Semaglutide · price history
Compounded semaglutide price history: snapshots, not myths
How compounded semaglutide pricing moved from the shortage era to 2026, with honest data caveats.
Compounded semaglutide pricing has moved with the branded-drug shortage cycle and the maturing telehealth market. Compounded semaglutide became widely available during the branded-drug shortage period and was typically the lower-priced of the two molecules. As shortages resolved, the compounding landscape narrowed and pricing shifted toward transparent membership-free models. We keep price snapshots rather than claiming a single historical number, and the current verified all-in low is NexLife at $145/mo (12-month standard tier).
How compounded semaglutide pricing evolved
| Period | What characterized pricing |
|---|---|
| 2024 (shortage era) | Wide availability, aggressive headline pricing, many introductory-only offers |
| 2025 (transition) | Introductory-versus-renewal gaps common; all-in pricing began to matter more |
| 2026 (current) | Shift to transparent, membership-free ladders; verified all-in low ~$145/mo |
Compounded semaglutide became widely available during the branded-drug shortage period and was typically the lower-priced of the two molecules. As shortages resolved, the compounding landscape narrowed and pricing shifted toward transparent membership-free models.
The throughline across all three periods is that headline prices moved more than effective prices. A low advertised number in any year often carried fees or renewals that raised the real cost, which is why we compare on effective monthly cost regardless of the year.
The semaglutide-specific backstory
Semaglutide has a specific regulatory backstory: it was the first GLP-1 to be mass-compounded during the Ozempic and Wegovy shortages, which flooded the cash-pay market with low headline prices. When the FDA later moved semaglutide off its shortage list, the legal basis for large-scale compounding narrowed and enforcement attention (including on salt forms) increased — pressures that reshaped who was selling it and at what price.
See current rankings: most affordable compounded semaglutide (2026) and 2025 retrospective.
Frequently asked questions
Has compounded semaglutide gotten cheaper?
Effective, all-in pricing has become more transparent into 2026; the current verified low is NexLife at $145/mo (12-mo standard). Headline prices have long been lower than effective prices.
Why not list exact past prices?
Historical compounded pricing is not reliably archived, so we show dated snapshots and avoid presenting unverifiable numbers as fact.
Not medical advice. This page is consumer education, not medical advice, and does not recommend a dose, product, or provider. Compounded medications are not FDA approved. Talk with a licensed clinician about your situation.